US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

3.97

+0.370010.28%

Post-market: 3.82-0.1500-3.78%19:55 EST

Volume:42.73K

Turnover:170.73K

Market Cap:3.85M

PE:-0.02

High:4.20

Open:3.70

Low:3.67

Close:3.60

52wk High:230.40

52wk Low:3.25

Shares:968.58K

Float Shares:967.93K

Volume Ratio:1.28

T/O Rate:4.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-190.7554

EPS(LYR):-1,128.6039

ROE:-2095.51%

ROA:-85.59%

PB:-1.91

PE(LYR):0.00

Loading ...

Overview Company News Filings

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Super League Enterprise Inc: Announces Strategic Partnership With Automatic Worlds

THOMSON REUTERS

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Press Release: Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia(R) in Japan and Certain Other Markets in the Asia-Pacific Region

Super League Enterprise Inc. Faces Nasdaq Delisting Over Failure to Meet Stockholders' Equity Requirement

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

BRIEF-Super League Announces Exclusive Partnership With ES3 To Deliver Branded Gamified Content Experiences Across Connected TV And Pay TV Platforms

Super League Announces Exclusive Partnership With Es3 to Deliver Branded Gamified Content Experiences Across Connected Tv and Pay Tv Platforms

THOMSON REUTERS

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

KYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan

MT Newswires Live

KYORIN Partners with Hinge Bio for SLE Drug Development in Japan

Super League Enterprise Inc. Announces Amendment to Convertible Note, Adjusts Conversion and Floor Prices

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

Super League Enterprise Inc. Announces Date for 2025 Annual Stockholders Meeting

Traders Eye Powell Speech as US Equity Futures Tread Water Pre-Bell

MT Newswires Live

Why Is Super League Enterprise Stock (SLE) Up 160% Today?

Top Premarket Gainers

MT Newswires Live

Super League Enterprise (SLE) Shares Soar After Hours: What's Happening?

Super League Gets $10M Investment From Evo Fund

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":3.97,"timestamp":1772226000000,"preClose":3.6,"halted":0,"volume":42730,"hourTrading":{"tag":"盘后","latestPrice":3.82,"preClose":3.97,"latestTime":"19:55 EST","volume":315,"amount":1212.43,"timestamp":1772240156019,"change":-0.15,"changeRate":-0.037783,"amplitude":0.037783},"delay":0,"changeRate":0.1027777777777778,"floatShares":967933,"shares":968577,"eps":-190.75543,"marketStatus":"Market Closed","change":0.37,"latestTime":"02-27 16:00:00 EST","open":3.7,"high":4.2,"low":3.67,"amount":170728.27049,"amplitude":0.147222,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-190.75543,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":3.6,"preHourTrading":{"tag":"盘前","latestPrice":3.78,"preClose":3.62,"latestTime":"09:29 EST","volume":171,"amount":622.3182822,"timestamp":1772202599260,"change":0.16,"changeRate":0.044199,"amplitude":0.063536},"postHourTrading":{"tag":"盘后","latestPrice":3.82,"preClose":3.97,"latestTime":"19:55 EST","volume":315,"amount":1212.43,"timestamp":1772240156019,"change":-0.15,"changeRate":-0.037783,"amplitude":0.037783},"volumeRatio":1.2849625638858095},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":967933,"roa":"-85.59%","roe":"-2095.51%","lyrEps":-1128.603888,"volumeRatio":1.2849625638858095,"shares":968577,"dividePrice":0,"high":4.2,"amplitude":0.147222,"preClose":3.6,"low":3.67,"week52Low":3.25,"pbRate":"-1.91","psRate":"0.33","week52High":230.4,"institutionHeld":0,"latestPrice":3.97,"eps":-190.75543,"divideRate":0,"volume":42730,"delay":0,"ttmEps":-190.75543,"open":3.7,"prevYearClose":7.326,"prevWeekClose":3.61,"prevMonthClose":5.4,"prevQuarterClose":7.326,"fiveDayClose":3.61,"twentyDayClose":6.19,"sixtyDayClose":11.3112},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3},{"market":"US","date":"2025-08-14","symbol":"SLE","fiscalQuarterEnding":"2025/06","expectedEps":-6.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-4.52},{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1763355600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-02-27","current":-0.020812,"percent":0.739865,"low":-0.738945,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"high":-0.044016,"avg":-0.284603,"sd":0.121049,"marketCap":3486877},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877}],"updateTime":1772335882551},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576005922","title":"Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576005922","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576005922?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168567/0/en/Vor-Bio-Announces-Late-Breaking-Oral-Presentation-of-China-Phase-3-IgA-Nephropathy-Clinical-Study-at-American-Society-of-Nephrology-s-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223082519.USD","BK4077","LU1223082196.USD","AFG","RA","BK4017","BK4117","CDE","BK4107","LU1223083913.SGD","SLE"],"gpt_icon":0},{"id":"2576503191","title":"Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576503191","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576503191?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698800,"startTime":"0","endTime":"0","summary":"Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up cli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168527/0/en/Climb-Bio-to-Present-Data-at-American-Society-of-Nephrology-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","AFG","BK4199","BK4107","ITP","SLE","BK4077"],"gpt_icon":0},{"id":"2575974135","title":"Super League Enterprise Inc: Announces Strategic Partnership With Automatic Worlds","url":"https://stock-news.laohu8.com/highlight/detail?id=2575974135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575974135?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:03","pubTimestamp":1760619814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX18F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2575874502","title":"Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874502","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874502?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616000,"startTime":"0","endTime":"0","summary":"Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167846/0/en/Vor-Bio-Announces-Publication-of-China-Phase-3-Study-of-Telitacicept-in-Systemic-Lupus-Erythematosus-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4077","SLE"],"gpt_icon":0},{"id":"2575594407","title":"Press Release: Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia(R) in Japan and Certain Other Markets in the Asia-Pacific Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2575594407","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575594407?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:30","pubTimestamp":1760560200,"startTime":"0","endTime":"0","summary":"-- Strengthens Viatris' Presence in Japan With the Addition of Two. Innovative Assets Targeting Areas of Significant Unmet Medical Need. -- Leverages Existing Infrastructure and Expertise in Central Nervous System. \"The acquisition of Aculys Pharma leverages our deep commercial infrastructure in Japan and longstanding expertise in CNS, positioning us to bring these innovative treatments to more patients in need,\" said Corinne Le Goff, Chief Commercial Officer, Viatris. \"The addition of pitolisant and Spydia to our portfolio of innovative products is strategically aligned with our commitment to grow in areas where we can make the greatest impact and is a great example of our business development strategy designed to complement our core strengths in markets across the world.\". Under the terms of the acquisition agreement, Viatris has made an upfront payment to Aculys Pharma shareholders as consideration for the acquisition, with additional considera","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","BK4077","BK4583","BK4215","VTRS","BK4081","BK4585","ESS","BK4135","LU2087621335.USD","SLE","BK4007","R","EMA","CNS","BK4022","BK4597","BK4232","BK4588"],"gpt_icon":0},{"id":"2575240801","title":"Super League Enterprise Inc. Faces Nasdaq Delisting Over Failure to Meet Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2575240801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575240801?lang=en_us&edition=fundamental","pubTime":"2025-10-15 05:01","pubTimestamp":1760475677,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. has announced that it is not in compliance with Nasdaq Listing Rule 5550, which requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. The company reported only $170,000 in stockholders' equity as of December 31, 2024, prompting a delisting determination letter from Nasdaq. Super League has requested a hearing to appeal the delisting, which will temporarily allow its common stock to remain listed pending the outcome. The company is seeking to address the issue through a proposed financing of at least $10 million, subject to stockholder approval at its upcoming annual meeting. Super League anticipates that this financing will restore compliance with Nasdaq's equity requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL42TR9t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2575290639","title":"Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575290639","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575290639?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443200,"startTime":"0","endTime":"0","summary":"Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166097/0/en/Telitacicept-Demonstrates-Clinically-Meaningful-and-Statistically-Significant-Impact-on-ESSDAI-Compared-to-Placebo-in-Late-Breaking-China-Phase-3-Results-in-Primary-Sj%C3%B6gren-s-Disea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","BK4110","RA","ACR"],"gpt_icon":0},{"id":"2574179220","title":"BRIEF-Super League Announces Exclusive Partnership With ES3 To Deliver Branded Gamified Content Experiences Across Connected TV And Pay TV Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2574179220","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574179220?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:06","pubTimestamp":1760101617,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Announces Exclusive Partnership With ES3 To Deliver Branded Gamified Content Experiences Across Connected TV And Pay TV PlatformsOct 10 (Reuters) - Super League Enterprise Inc SLE.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nTUA28HRPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2574179647","title":"Super League Announces Exclusive Partnership With Es3 to Deliver Branded Gamified Content Experiences Across Connected Tv and Pay Tv Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2574179647","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574179647?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:00","pubTimestamp":1760101201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nTUA28HRPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2573946727","title":"Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2573946727","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573946727?lang=en_us&edition=fundamental","pubTime":"2025-10-08 17:00","pubTimestamp":1759914000,"startTime":"0","endTime":"0","summary":"- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multipl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163133/0/en/Zenas-BioPharma-and-InnoCare-Pharma-Announce-License-Agreement-Granting-Zenas-Rights-for-Three-Autoimmune-Product-Candidates-Including-Orelabrutinib-a-BTK-Inhibitor-in-Phase-3-Deve.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU1720051108.HKD","LU1244550494.USD","ZBIO","LU1732799900.SGD","LU0795875086.SGD","LU1162221912.USD","LU0267386448.USD","BK4585","LU2347655156.SGD","LU2089283258.USD","LU2357305700.SGD","LU1989772840.SGD","LU2271345857.HKD","IE00BKVL7J92.USD","LU1548497426.USD","LU0098860793.USD","BK4077","LU1989772923.USD","BK4504","BK4581","BK4534","LU0225283273.USD","BK4563","LU0158827781.USD","BK4503","LU1720051017.SGD","SLE","QD","LU2023251221.USD","BK4588","EMA","BK4516","LU1732800096.USD","CEO","LU0158827948.USD","BK4127","LU0882574139.USD","LU2111349929.HKD","LU0314104364.USD","LU1244550221.USD","BK4166","LU0106831901.USD","LU0971096721.USD","BK4139","LU1668664300.SGD","BK4081","LU0912757837.SGD","LU0795875169.SGD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2572585893","title":"KYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2572585893","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572585893?lang=en_us&edition=fundamental","pubTime":"2025-10-01 14:12","pubTimestamp":1759299122,"startTime":"0","endTime":"0","summary":"KYORIN Pharmaceutical  said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus , along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2572130302","title":"KYORIN Partners with Hinge Bio for SLE Drug Development in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2572130302","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572130302?lang=en_us&edition=fundamental","pubTime":"2025-10-01 07:52","pubTimestamp":1759276344,"startTime":"0","endTime":"0","summary":"An announcement from KYORIN Pharmaceutical Co.,Ltd. ( ($JP:4569) ) is now available. KYORIN Pharmaceutical Co., Ltd. has entered into an exclusive ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyorin-partners-with-hinge-bio-for-sle-drug-development-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyorin-partners-with-hinge-bio-for-sle-drug-development-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2572371592","title":"Super League Enterprise Inc. Announces Amendment to Convertible Note, Adjusts Conversion and Floor Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2572371592","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572371592?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:12","pubTimestamp":1759263160,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. has announced an update to its financing arrangement with Yield Point NY, LLC. The conversion price for its convertible note has been set at $5.95 per share, with a minimum price of $1.19. The company says all other terms remain unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL9NnDZt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2571387981","title":"Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387981?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:00","pubTimestamp":1759143600,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  29, 2025  (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157572/0/en/Vor-Bio-Announces-Late-Breaking-Poster-Presentation-of-Phase-3-Primary-Sj%C3%B6gren-s-Disease-Clinical-Study-at-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","LU1223082519.USD","BK4077","ACR","LU1223083913.SGD","SLE","CDE","RA","LU1223082196.USD","BK4110"],"gpt_icon":0},{"id":"2569712518","title":"Super League Enterprise Inc. Announces Date for 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712518?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:34","pubTimestamp":1758645296,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc. has announced that its 2025 annual meeting of stockholders will be held virtually on October 2025. During the meeting, stockholders will vote on the re-election of one current director and the election of the current President and Chief Executive Officer to serve as Class II directors until the 2028 annual meeting of stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL7L5c0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2569713522","title":"Traders Eye Powell Speech as US Equity Futures Tread Water Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2569713522","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569713522?lang=en_us&edition=fundamental","pubTime":"2025-09-23 21:10","pubTimestamp":1758633056,"startTime":"0","endTime":"0","summary":"US equity futures were flat ahead of Tuesday's opening bell as traders awaited a speech from Federal Reserve Chair Jerome Powell.Dow Jones Industrial Average futures were 0.1% higher, while S&P 500 fu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ea1543c7dfd7fef8e85c2b8e24e18774","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TQQQ","SLE","TSYW.SI",".SPX","USJW.SI","LU0742534661.SGD","BK4096","US2Y.BOND","NVIW.SI","LU0314104364.USD",".IXIC","FLY","US10Y.BOND","QID","LU1935043536.SGD","UDOW","LU0251142724.SGD","MNQmain","PSQ","LU2362540622.SGD","SRE","IE00B3QW5Z07.USD","DDM","SDOW","US30Y.BOND","US12M.BOND","IE000M9KFDE8.USD",".DJI","DOG","US7Y.BOND","KKR","NQmain","EQR","LU1621767810.EUR","BK4135","MYMmain","US3Y.BOND","DXD","LU0648001328.SGD","QLD","USAW.SI","TLTW","US5Y.BOND","DJX","SQQQ","US6M.BOND"],"gpt_icon":1},{"id":"2569972997","title":"Why Is Super League Enterprise Stock (SLE) Up 160% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569972997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569972997?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:01","pubTimestamp":1758628869,"startTime":"0","endTime":"0","summary":"Super League Enterprise stock rallied alongside new plans for a private placement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-super-league-enterprise-stock-sle-up-160-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-super-league-enterprise-stock-sle-up-160-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2569797803","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2569797803","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569797803?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:45","pubTimestamp":1758627923,"startTime":"0","endTime":"0","summary":"Super League Enterprise (SLE) shares were 164% higher pre-bell Tuesday after the company said late Monday it secured a $10 million strategic equity investment from Evo Fund.Galecto (GLTO) stock was up","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IPDN","BK4130","BETR","BK4082","BK4077","BK4229","GLTO","SSKN","SLE"],"gpt_icon":0},{"id":"2569104753","title":"Super League Enterprise (SLE) Shares Soar After Hours: What's Happening?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569104753","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569104753?lang=en_us&edition=fundamental","pubTime":"2025-09-23 05:42","pubTimestamp":1758577320,"startTime":"0","endTime":"0","summary":"Shares of micro-cap playable media company Super League Enterprise Inc SLE are soaring in extended trading on Monday after the company announced an investment from Evo Fund.SLE stock is showing exceptional strength. Get the market research here.What Happened: Super League Enterprise entered into a definitive agreement for private placement financing anchored by a$10 millionstrategic equity investment from digital asset treasury investor Evo Fund.The company anticipates a total of $12 million to $20 million in gross proceeds from the private placement, which will be used to help the company regain compliance with Nasdaq listing requirements and complete the final step of its corporate restructuring. Super League noted that it intends to pursue a digital asset strategy.For Super League Enterprise, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends wi","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/22/Stock-Market-Graph-Trading-Analysis-Inve.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/22/Stock-Market-Graph-Trading-Analysis-Inve.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/09/47808114/super-league-enterprise-sle-shares-soar-after-hours-whats-happening","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/09/47808114/super-league-enterprise-sle-shares-soar-after-hours-whats-happening","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2569975812","title":"Super League Gets $10M Investment From Evo Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2569975812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569975812?lang=en_us&edition=fundamental","pubTime":"2025-09-23 05:07","pubTimestamp":1758575220,"startTime":"0","endTime":"0","summary":"Super League said it would execute a private placement that would land it $12 million to $20 million in proceeds, including a $10 million investment from Evo Fund, a cryptocurrency investment company.The placement is expected to close following Super League's stockholder meeting in October.The video game company said the stock sale would allow it to clear its debt and pursue cryptocurrency opportunities. The financing will also enable it to regain compliance with the Nasdaq's listing requirements.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":104,"code":"91000000","status":"200"}]}}